Добірка наукової літератури з теми "ANTIHISTAMINE DRUGS"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "ANTIHISTAMINE DRUGS".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "ANTIHISTAMINE DRUGS"
1
Maeda, Toshiki, Akira Babazono, and Takumi Nishi. "Surveillance of First-Generation H1-Antihistamine Use for Older Patients with Dementia in Japan: A Retrospective Cohort Study." Current Gerontology and Geriatrics Research 2018 (July 2, 2018): 1–6. http://dx.doi.org/10.1155/2018/3406210.
Повний текст джерелаАнотація:
Background. This study aimed to investigate the rate of first-generation H1-antihistamines use for older adults with dementia in Japan. Methods. The study design was retrospective cohort using claims data between fiscal years 2010 and 2013. Subjects were 75 years or older, diagnosed with dementia, and given H1-antihistamines orally during the study period after being diagnosed with dementia. We investigated the cumulative number of oral H1-antihistamines administered and the relationship between first-generation H1-antihistamine use and each explanatory variable using crude and adjusted odds ratio. Results. The cumulative total for use of first-generation H1-antihistamine for older adults with dementia accounted for 32.1% of all antihistamine medication. The majority of first-generation H1-antihistamine prescriptions were indicated for cold treatment. Those with upper respiratory infection or asthma had a significantly positive relationship with first-generation H1-antihistamine use. Conclusion. The study showed that first-generation H1-antihistamine drugs were highly prescribed in older adults with dementia in Japan.
2
Oyekan, P. J., H. C. Gorton, and C. S. Copeland. "Over-the-counter antihistamines in drug-related deaths: a population-based case series." International Journal of Pharmacy Practice 29, Supplement_1 (March 26, 2021): i30—i31. http://dx.doi.org/10.1093/ijpp/riab015.037.
Повний текст джерелаАнотація:
Abstract Introduction Antihistamines are not one of the medicine groups reported on in the Office for National Statistics drug-related death data. (1) However, there is concern that first-generation antihistamines are misused for their sedative properties. This is amplified by a recent social media challenge, which resulted in deaths due to diphenhydramine overdose. (2) The extent of the involvement of antihistamines in deaths is largely unknown. Aim We aimed to evaluate deaths related to antihistamines in England (2000–2019) by individual drug, medicine classification (POM, P, GSL), whether the drug was considered attributable to the death (known as implication rate), or incidental; and examine temporal trends. Methods Deaths are reported voluntarily by coroners to the National Programme on Substance Abuse Deaths (NPSAD) in cases where psychoactive drugs were detected at post-mortem and/or when the decedent was known to abuse drugs. NPSAD holds data on decedent demographics (gender, age, employment status, living arrangements), details pertaining to the death (cause(s) of death, manner of death, conclusion of inquest, toxicology reports) and past social and medical histories, including drugs prescribed. From this dataset, we extracted all cases where an antihistamine was detected at post-mortem between 2000 and 2019. We report descriptive statistics to describe the reporting of antihistamines in deaths. Results We identified 1666 antihistamine detections from 1537 individuals. The significant majority of these were sedative antihistamines which are classed as pharmacy medicines (P) (85.2%, p<0.01); deaths where prescription-only antihistamines were detected represented fewer than 7.0% of cases. Despite an increasing trend for antihistamine detections in deaths over time, the proportion of deaths where the detected antihistamine was implicated in causing the death declined over the same period (average implication rate 2000–2005: 58.7%; 2014–2019: 28.4%). Whilst death was deemed accidental in the majority of cases (66.1%), a significant proportion of cases were concluded as suicide (20.9%, p<0.01).Polydrug use was evident in the vast majority of cases (98.5%), with central nervous system depressants the most commonly co-administered substances (94.8% of cases). Conclusion We describe the first report regarding antihistamine-related mortality from England. From the NPSAD, we can obtain prescription source and toxicology reports, beyond those reported in national death data. Although incomplete, the response from coroners is good (89%), and provides sufficient cause for concern. The rising trend in antihistamine-related deaths may in-part be contributed to by the perceived negligible dangers associated with antihistamines, both from the general public and professionals. Awareness of the dangerous sedative properties that some antihistamines possess is however heightened in individuals who are deliberately seeking out these effects. An urgent review of sedating antihistamines currently assigned under the P classification is needed to achieve antihistamine harm reduction, balanced against the self-care they enable. References 1. Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2019 registration [internet]. 2020 [cited 18 Oct 2020]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2019registrations 2. US FDA. Benadryl (diphenhydramine): Drug Safety Communication - Serious Problems with High Doses of the Allergy Medicine. 2020.
3
Shabanov, D. V., and Ju E. Lutkovskaya. "Actual antihistamine therapy." Meditsinskiy sovet = Medical Council, no. 16 (November 14, 2020): 26–35. http://dx.doi.org/10.21518/2079-701x-2020-16-26-35.
Повний текст джерелаАнотація:
The significance of the issues of allergic diseases is not in doubt. It is difficult to find a person who has not suffered at least some Allergy symptom, not everyone develops diseases, but most people face Allergy symptoms. The prevalence of various allergic diseases is increasing every year, currently reaching 30% of the population, and the world health organization predicts it will reach 50% in the next few decades. The most common nosologies are allergic rhinitis, bronchial asthma, atopic dermatitis, urticaria, but there are many other conditions of hypersensitivity. This article addresses the issues of inflammatory reactions in General and specifically allergic inflammation, discusses the main aspects of the pathogenesis of allergic rhinitis and urticaria, and questions of drug therapy for these diseases. Most people are sure that they can take anti-allergic medications for allergies, and most often they are referring to antihistamines. Unfortunately, even some medical specialists lack an understanding of the specifics of antihistamine therapy. some people still believe that there are three or four generations of antihistamines, and patients use drugs not as prescribed by doctors, but on the recommendation of friends or pharmacists. Irrational use of antihistamines leads to a decrease in effectiveness, and it is not uncommon to discredit specific drugs and groups of drugs in General. This article demonstrates the results of various European and Asian studies on the effectiveness and safety of antihistamines and bilastin in particular, as well as their own experience of using antihistamines in practice.
4
Vuković, Milana, Dunja Vesković, Nemanja Todorović, Tatjana Roš, Jasmina Jovanović-Ljubičić, Danilo Kuzman, Mladena Lalić-Popović, Dejan Miljković, and Boris Milijašević. "Comparative analysis of the consumption of antihistamines for systemic use in the Republic of Serbia and Nordic countries in the period 2009-2019." Hospital Pharmacology - International Multidisciplinary Journal 10, no. 1 (2023): 1250–63. http://dx.doi.org/10.5937/hpimj2301250v.
Повний текст джерелаАнотація:
Introduction: According to the ATC system of drug classification, group R06 includes H1 antihistamines for systemic use, which are divided into drug groups of the 1st and 2nd generation. Aim: Since there are no national guidelines in Serbia, for treating most allergic diseases, our aim was to compare pharmaceutical products and treatment strategies of systemic antihistamines use in Serbia with that in the Nordic countries that have been recognized as countries with good pharmacoeconomic practice. Material and methods: Data on drug consumption in the Republic of Serbia, the Kingdom of Norway, the Republic of Finland, and the Kingdom of Denmark were collected from the publications of national drug regulatory agencies for the period from 2009 to 2019. Results: Loratadine was the most commonly consumed antihistamine in Serbia in 2009, making 72.32% of the total consumption of drugs in the R06 group. During observed period the consumption of cetirizine increased 21.8 times, levocetirizine increased 36.6 times, desloratadine increased 2.6 times. The most commonly used antihistamines in Serbia in 2016 were: loratadine with 34.86%, followed by desloratadine with 18.70%, and ketotifen with 14.52% of the total consumption of drugs in the R06 group. In 2019, the most commonly used antihistamines were levocetirizine, loratadine, desloratadine and cetirizine. In Norway as well as in Finland and Denmark, during all eleven years (2009-2019) cetirizine was the most consumed antihistamine with mild increase trend in consumption of 1.5-5.74-20.5%. The second most consumed antihistamine in Norway and in Finland was desloratadine and in Denmark, fexofenadine. A decrease in consumption was recorded in case of loratadine in all three Scandinavian countries. First generation antihistamines promethazine and dexchlorpheniramine showed a continuous but minimal downward trend. Conclusion: Unlike Norway, Sweden and Denmark, in Serbia in the last 11 years, the consumption trends of antihistamines have not been consistent and seem to depend on various factors such as price.
5
Cho, Kyoo H., Ji E. Lee, Sook K. Song, and Phil Hyu Lee. "Chorea induced by antihistamine drugs." Movement Disorders 25, no. 4 (January 27, 2010): 519–20. http://dx.doi.org/10.1002/mds.22965.
Повний текст джерела
6
Kareva, E. N. "Pharmacological optimization of antihistamine profile." Russian Medical Inquiry 6, no. 2 (2022): 92–97. http://dx.doi.org/10.32364/2587-6821-2022-6-2-92-97.
Повний текст джерелаАнотація:
Antihistamines are the first-line treatment for allergic diseases. The optimization of pharmacological properties of these pharmacotherapeutics is provided by the synthesis of new molecules with better safety profile (no penetration via the blood-brain barrier or less risk of drug interactions) or more selective affinity to H1-receptors (active optical isomer). In real clinical practice, drugs with extrahepatic metabolism have an advantage, the effectiveness of which does not depend on concomitant therapy, and the maximum concentration is reached in the shortest possible time, which ensures a rapid onset of action. Comfort use and, therefore, adherence to treatment is also an essential aspect of pharmacotherapy. Current orodispersible H1-receptor antagonists have a clinically significant antihistamine effect and agree with patient expectations due to comfort use and no need to take them with water. As a result, these medications are suitable for specific categories of individuals, e.g., children, patients with difficulty of swallowing, and people practicing an active lifestyle. KEYWORDS: histamine, antihistamines, levocetirizine, pharmacokinetics, pharmacodynamics, orodispersible forms, compliance. FOR CITATION: Kareva E.N. Pharmacological optimization of antihistamine profile. Russian Medical Inquiry. 2022;6(2):92–97 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-92
7
Tsarev, S. V. "Antihistamine therapy in pediatric practice." Medical Council, no. 11 (July 16, 2018): 136–39. http://dx.doi.org/10.21518/2079-701x-2018-11-136-139.
Повний текст джерелаАнотація:
The article considers the role of histamine in the pathogenesis of allergic diseases and other pathological conditions. The mechanisms that contribute to the development of skin itching are considered separately. The article also shows the role and function of H1-histamine receptor blockers in the treatment of allergic diseases and pseudo allergic reactions. The mechanism of action, indications, contraindications and side effects of the antihistamine therapy are presented. The article also discusses the difference in first and second-generation antihistamines and shows the possible advantages of the first-generation drugs in paediatric practice. The article presents data on the use of dimethindene maleate (Fenistil) in children’s practice, including the use for the relief of skin itching of various genesis.
8
Stahl, Stephen M. "Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines." CNS Spectrums 13, no. 12 (December 2008): 1027–38. http://dx.doi.org/10.1017/s1092852900017089.
Повний текст джерелаАнотація:
Numerous “antihistamines” as well as various psychotropic medications with antihistamine properties are widely utilized to treat insomnia. Over-the-counter sleep aids usually contain an antihistamine and various antidepressants and antipsychotics with antihistamine properties have sedative-hypnotic actions. Although widely used for the treatment of insomnia, many agents that block the histamine H1 receptor are also widely considered to have therapeutic limitations, including the development of next-day carryover sedation, as well as problems with chronic use, such as the development of tolerance to sedative-hypnotic actions and weight gain. Although these clinical actions are classically attributed to blockade of the H1 receptor, recent findings with H1 selective agents and H1 selective dosing of older agents are challenging these notions and suggest that some of the clinical limitations of current H1-blocking agents at their currently utilized doses could be attributable to other properties of these drugs, especially to their simultaneous actions on muscarinic, cholinergic, and adrenergic receptors. Selective H1 antagonism is emerging as a novel approach to the treatment of insomnia, without tolerance, weight gain, or the need for the restrictive prescription scheduling required of other hypnotics.
9
Lisni, Ida, Ani Anggriani, and Regina Puspitasari. "KAJIAN PERESEPAN OBAT ANTIHISTAMIN PADA PASIEN RAWAT JALAN DI SALAH SATU RUMAH SAKIT DI BANDUNG." Jurnal Riset Kefarmasian Indonesia 2, no. 2 (May 1, 2020): 52–62. http://dx.doi.org/10.33759/jrki.v2i2.77.
Повний текст джерелаАнотація:
Histamine is one of the factors that cause acute and chronic disorders, so it is necessary to investigate further the mechanism of antihistamines in the treatment of allergic diseases. Antihistamines are substances that can reduce or block the effects of histamine on the body by blocking histamine receptors. Antihistamines are one of the drugs that are often prescribed to children to the elderly. Thus the application of therapy in medicine is needed to ensure the use of appropriate drugs to prevent the occurrence of medication errors so that the goal of therapeutic effectiveness can be achieved. The purpose of this study was to determine the prescribing pattern of antihistamine drugs and assess the accuracy of the administration of antihistamines based on dose accuracy and potential drug interactions. Prescribing studies of this drug are descriptive quantitative and qualitative by using data sources in the form of patient prescription sheets taken retrospectively. The results of quantitative research data show that patients 57.23% were female, the highest age was 55-59 years old 12.26%, the most widely used drug was setirizine 72.48%, dose accuracy 89.60% and more doses 10.40%, the potential for drug interactions occurred in 27.83%, The drug that has the most potential for interaction is setirizine with theophylline.
10
Assadi, Sara, Latif Rahman, Mark Kong, and Sukaina Asad. "Could the Use of Antihistamines Have Triggered Reversible Cerebral Vasoconstriction Syndrome? A Case Report." Case Reports in Acute Medicine 4, no. 2 (June 28, 2021): 50–57. http://dx.doi.org/10.1159/000517115.
Повний текст джерелаАнотація:
A 38-year-old woman presented to the emergency department with recurrent severe headaches. Although initial computer tomography (CT) brain imaging was unremarkable, a later CT venogram demonstrated a small subarachnoid haemorrhage. Magnetic resonance angiogram (MRA) brain imaging subsequently confirmed reversible cerebral vasoconstriction syndrome (RCVS). In the acute setting, RCVS rarely falls into a differential diagnosis for headache presentations, as in this case. The radiological variability can make diagnosis of RCVS challenging. However, there are clinical consistencies that can aid physicians into accurately diagnosing RCVS. A thorough history, including a medication history, can help identify potential triggers of RCVS. As in this case, the combination of commonly used drugs, including antihistamines, provides a plausible trigger for RCVS. The direct vasoactive role of antihistamines is unclear, yet there is suggestion for its ability to potentiate the vasoactive action of other drugs. In this case we propose a causal relationship between the use of antihistamine and the development of RCVS.
Дисертації з теми "ANTIHISTAMINE DRUGS"
1
Baxter, R. I. "Voltammetric studies of some important antihistamine drugs." Thesis, Queen's University Belfast, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.374204.
Повний текст джерела
2
Shamsi, Ziba. "Measurement of drug action in man : psychometric aspects of antihistamines." Thesis, University of Surrey, 1999. http://epubs.surrey.ac.uk/843065/.
Повний текст джерелаАнотація:
The use of antihistamines (AHs) has until recently been associated with a number of undesirable side effects, the most troublesome of which is sedation. There are two aspects to sedation. The first, an objectively determined measure based on the results of psychometric tests from controlled trials, and the second, the subject's response to the administration of a drug. Since AHs are largely used in ambulant patients, a complete evaluation of sedation should be performed through standardised objective tests, shown to be sensitive to the central effects of AHs and reliable ratings of subjective experiences. A critical review of the literature on the experimental studies with AHs revealed that the traditional AHs had a greater propensity to produce adverse central nervous system (CNS) effects, whereas the so called second generation AHs were generally less impairing when administered within their recommended 'dose window'. A similar review of the clinical literature surveying subjective reports of sedation following the administration of AHs showed that the traditional AHs were perceived as more sedative than the second generation AHs. On the basis of these findings, a series of controlled experiments in non-atopic volunteers investigated the effects of a number of second generation AHs on various aspects of cognitive functioning and psychomotor performance. It is concluded that the second generation AHs have a lesser effect with respect to objective indices of sedation when compared to their predecessors, and that fexofenadine, has a claim to be the first truly non-sedating antihistamine as there is no objective evidence of CNS effects. The identification of an antihistamine, devoid of adverse CNS activity regardless of the administered dose, highlights the need for the introduction of a 'third generation' of AHs.
3
Schooley, Elizabeth K. "The effects of an antiseritonergic drug and antihistamine in an experimental model of feline asthma." Diss., Columbia, Mo. : University of Missouri-Columbia, 2007. http://hdl.handle.net/10355/5033.
Повний текст джерелаАнотація:
Thesis (M.S.)--University of Missouri-Columbia, 2007.The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Vita. "May 2007" Includes bibliographical references.
4
Mousa, Aisha H. "Characterization of a novel histamine G protein-coupled receptor from Schistosoma mansoni (SmGPCR)." Thesis, McGill University, 2002. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=79055.
Повний текст джерелаАнотація:
A G protein-coupled receptor with structural characteristics of a biogenic amine GPCR was cloned from Schistosoma mansoni (SmGPCR). SmGPCR was codon-optimized and double-tagged with FLAG and His epitopes at the N- and C-terminal ends, respectively. Immunofluorescence experiments targeting these epitopes revealed that the expression of codon-optimized SmGPCR was highly increased compared to wild-type in mammalian cells. These studies also demonstrated that SmGPCR has a typical GPCR topology, the N-terminus being extracellular and C-terminus intracellular. Functional assays revealed that codon-optimized SmGPCR was responsive only to histamine, which caused a dose-dependent increase in intracellular Ca2+ (EC50 = 0.54 +/- 0.05 muM), but not cAMP, consistent with a Gq pathway of signal transduction. In vitro behavioral studies showed that treatment of S. mansoni cercaria with exogenous histamine caused a dose-dependent increase in the motility of the parasite.
5
Fernandes, João Paulo dos Santos. "Planejamento e sintese de compostos potencialmente ligantes dos receptores 5-HT2C e H4." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/9/9138/tde-18022013-135502/.
Повний текст джерелаАнотація:
A serotonina e a histamina são duas das mais importantes aminas biogênicas do organismo. Regulam série de funções fisiológicas, como fluxo sanguíneo, temperatura corpórea, sono, fome, liberação de hormônios, comportamento afetivo e humor, entre outras. Assim, há grande interesse no planejamento e desenvolvimento de fármacos que interferem na transmissão serotoninérgica e histaminérgica, para futura aplicação como antidepressivos, antipsicóticos, ansiolíticos e anorexígenos, além de perifericamente, apresentarem possíveis ações antiinflamatórias. O objetivo deste trabalho é apresentar a síntese de compostos contendo os núcleos pirrolquinolínico, benzoindólico e benzodiidrofurânico com potencial atividade ligante nos receptores 5-HT2C e H4, assim como avaliar a seletividade desses compostos em comparação aos receptores 5-HT2A/B e H3. Sintetizou-se série de compostos utilizando reações de alilação, adição à carbonila, termociclização, rearranjo de Claisen, iodociclização e substituição nucleofílica para a obtenção dos compostos finais. Estudos de otimização de síntese por metodologia de superfície de resposta também são apresentados, assim como estudos de relações quantitativas entre estrutura química e atividade biológica de compostos ligantes dos receptores 5-HT2C e H4.Serotonin and histamine are two major biogenic amines in the body. They regulate several physiological functions such as blood flow, body temperature, sleep, hunger, hormone release, emotional behavior and mood, among others. Thus, there is great interest in the design and development of drugs that interfere with serotoninergic and histaminergic transmission, for future use as antidepressants, antipsychotics, anxiolytics and anorectic, and peripherally, possible anti-inflammatory actions. The aim of this work is to present the synthesis of compounds containing the pyrroloquinoline, benzoindole and benzodihydrofurane nucleus with potential binding activity to 5-HT2C and H4 receptors, as well as to evaluate the selectivity of these compounds in comparison to 5-HT2A/B and H3. Series of compounds were synthesized using allylation, carbonyl addition, thermal cyclization, Claisen rearrangement, iodocyclization and nucleophilic substitution reactions. Optimization studies for the synthesis using response surface methodology are also presented, as well as quantitative structure-activity relationships studies of ligands of 5-HT2C and H4 receptors.
6
Ciurlizza, Celis Claudia Paola. "Aportación al estudio de permeación transdérmica de cetirizina." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/457668.
Повний текст джерелаАнотація:
Actualmente los antihistamínicos son muy utilizados en el tratamiento de patologías relacionadas con procesos alérgicos, tanto aplicados directamente sobre la piel para obtener un efecto local, como administrados por vía oral. Sin embargo, en el transcurso de los últimos años, se ha puesto de manifiesto que puede utilizarse la piel como vía de administración de fármacos, formulados de tal forma que el principio activo desarrolle una acción sistémica. Así pues, el empleo de la vía dérmica y de la transdérmica como alternativa a la vía oral, ha dado lugar a un avance en cuanto al conocimiento de la estructura de la piel y en cuanto a los mecanismos de transporte de sustancias a través de ella. Cabe considerar que una de las líneas de investigación aplicada en el campo de la industria farmacéutica es el diseño de nuevos sistemas de liberación de fármacos sobre la piel (parches transdérmicos, liposomas, microemulsiones, nanoemulsiones, etc), que contienen excipientes novedosos y promotores de la permeación cutánea que permitan alcanzar el objetivo deseado: liberación local, regional o transdérmica del fármaco.
Por lo tanto, resulta interesante estudiar las características de permeación cutánea de la cetirizina en piel humana, vehiculizada en sistemas de liberación nanoestructurados destinados al tratamiento de alteraciones patológicas locales que cursen con procesos alérgicos.
Así pues, el objetivo principal del presente proyecto de tesis consiste, en la obtención de formulaciones nanoestructuradas de cetirizina (hidrogel y nanoemulsión) con el fin de obtener un efecto antihistamínico local, por un lado, y un efecto sistémico por el otro.
Para llevar a cabo este objetivo, se realiza un estudio “ex vivo” de la absorción transdérmica de cetirizina con distintos promotores, así, también se optimizan las formulaciones por medio de redes neuronales con el fin de obtener concentraciones plasmáticas predichas dentro del intervalo terapéutico, por último, se desarrolla y evalúa una formulación nanoestructurada de cetirizina para la obtención de un efecto local tópico sobre la piel.
El estudio de permeación transdérmica del hidrogel y de la nanoemulsión al 5% de cetirizina, demostró que sólo la nanoemulsión penetró a través de la piel después de 19h de la aplicación tópica, a pesar de esto, el flujo, el tiempo de latencia y el coeficiente de permeabilidad resultaron ser bajos. Pequeñas cantidades de la dosis tópica aplicada son absorbidas y las concentraciones séricas están significativamente por debajo del rango terapéutico (0,257-0,384 μg/ml). Parece que la aplicación tópica de cetirizina es óptima sólo para un efecto de aplicación local.
La velocidad de liberación de cetirizina para las nanoemulsiones fueron estadísticamente más bajas cuando se compararon con los hidrogeles. Ambos vehículos proporcionaron una liberación sostenida de cetirizina, siendo los hidrogeles los más adecuados, ya que se alcanzó un 75% de fármaco liberado en 6 horas.
En el estudio de la actividad antihistamínica del hidrogel y de la nanoemulsión de cetirizina en conejos, estadísticamente no se observaron diferencias, pero se pudo observar que el hidrogel demostró el efecto máximo en 30 min. El antihistamínico comercial, la dexclorfeniramina, exhibió levemente mayor reducción de la pápula que el hidrogel de cetirizina (14,12 y 12,60%), seguida por el dimetindeno maleato (9,02%) y finalmente la nanemulsión (8,32%).
En la búsqueda y selección de formulaciones transdérmicas de cetirizina con ayuda de redes neuronales artificiales, se construyó un test de 89 vectores de entrada, “xi pertenece a R18”, donde cada xi representa la composición de una formulación propuesta en términos de 18 constituyentes (agua, propilenglicol, transcutol, isostearato, etc.), como en el conjunto de entrenamiento. Las veintiuna redes entrenadas se aplicaron a las entradas de test para predecir los valores de las cuatro características (J (μg/h), Tl (h), Kp (cm/h) y Cee (μg/mL)) para cada nueva formulación. A partir de estas predicciones, se seleccionaron siete formulaciones candidatas para las que al menos el 50% de las redes (incluyendo la lineal) predijeron resultados satisfactorios, y en dos de ellas (las más prometedoras) al menos el 75% de las redes coincidieron.
Actualmente no existe en el mercado farmacéutico antihistamínicos de segunda generación disponibles para ser administrados por vía tópica, por lo que se puede concluir de acuerdo con los estudios realizados en este proyecto de tesis, que la nanoemulsión de cetirizina diclorhidrato es un sistema prometedor para el tratamiento de alergias producidas en la piel.
7
Wu, Jia-Syuan, and 吳佳璇. "Analyzing the Allergic Reactions Induced by the Chemotherapy Regimens Including Oxaliplatin and Evaluating the Effectiveness of Receiving Preventive Antihistamine Drugs." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/66498648402200227481.
Повний текст джерелаАнотація:
碩士高雄醫學大學
藥學研究所碩士在職專班
102
【Background】 According to the latest 2011 cancer registration report announced by Taiwan Health Promotion Administration, Ministry of Health and Welfare, the incidence of gastric cancer is ranked No. 6 in males and No. 8 in females, while the incidence of colorectal cancer ranked No. 1 in males and ranked No. 2 in females. Oxaliplatin is currently one of the main drugs of chemotherapy for colorectal cancer and end-stage gastric cancer. Oxaliplatin is a third- generation platinum compound, which is approved by the National Health Insurance Bureau for treatment of stage III colon-rectal cancer, metastatic colorectal cancer and partially end-stage or metastatic gastric cancer. According to many studies, about 90% of the patients who have received oxaliplatin treatments are accompanied by peripheral neuropathy, whose grade is related to the dosage of oxaliplatin. Most of these adverse events can recover during the chemotherapy cycles. The clinical medical staff can provide patients with instructions to against these adverse drug reactions. However, registered allergic reactions as another adverse drug reaction of oxaliplatin, besides neuropathy, are increasing in recent years, severe allergic reactions even interrupted ongoing oxaliplatin treatments because some of the patients came to the end of endurance. Objective : During the clinical treatment, patients are given antihistamine drugs to alleviate allergic reactions induced by oxaliplatin, and it is successful in most of them. Due to the effect, some clinical doctors give the patients antihistamine drugs in advance to prevent allergic reactions before the patients receive oxaliplatin infusions. However, on the one side, antihistamine drugs often cause dizziness, nausea, or conscious disturbance. On the other side, the antihistamine drugs cannot prevent some patients effectively from oxaliplatin-induced allergic reactions by clinical observation. Because there is no relevant guideline for the prevention from oxaliplatin-induced allergic reactions, this study aims to evaluate the effectiveness of the prevention of antihistamine drugs against oxaliplatin-induced allergic reactions in order to provide information on clinical treatment and post-treatment care. 【Methods】 This is a retrospective case-control study with subjects composed of patients who have allergic reactions after receiving oxaliplatin infusions from January 2008 to May 2013 in a medical center in southern Taiwan. The subjects are divided into two groups: the study group consisted of patients without taking antihistamine drugs before the oxaliplatin infusion; the control group consisted of patients taking antihistamine drugs before the oxaliplatin infusions. By means of case review and combining with the adverse drug reaction registration system in the hospital, we analyze the incidence of oxaliplatin-induced allergic reactions and the grade of allergic reactions. The data are processed and analyzed by SPSS 19.0 for Windows and explained with descriptive statistics of percentage, mean value, median value and standard deviation, as well as inferential statistics of Chi-Square test and 95% confidence interval analysis. 【Results】 There were 545 patients receiving oxaliplatin infusions from January 2008 to May 2013. Finally 535 patients are included for analysis, including 85 patients (15.6%) reported with allergic reactions, which occurred after a median of the eighth infusion of oxaliplatin. 61 patients of them received oxaliplatin re-challenge; 46 of these 61 patients (75.4%) led to further reactions, and 24 patients (28.2%) stopped their oxaliplatin treatment owing to intolerance to oxaliplatin-induced allergic reactions. The symptoms of oxaliplatin-induced allergic reactions are primarily skin rashes (76.5%), secondly shortness of breath and chest tightness (32.3%), sweating, vomiting and so on. These 535 patients receiving oxaliplatin infusions were divided into two groups, 164 patients without receiving antihistamine drugs before the oxaliplatin infusion in the study group, and 371 patients receiving antihistamine drugs before the oxaliplatin infusion in the control group. 27 patients (16.46%) in the study group had allergic reactions, while allergic reactions happened to 58 patients (15.22%) in the control group. The rates of oxaliplatin-induced allergic reactions show no statistically significant difference (P> 0.05) between the two groups, revealing that receiving antihistamine drugs before the oxaliplatin infusion cannot effectively prevent allergic reactions. 【Conclusion】 This study reveals that the effectiveness of giving patients in the study group antihistamine drugs to prevent allergic reactions caused by oxaliplatin had no statistically significant difference from that in the control group. It was also found that giving antihistamine drugs in advance not only increases side effects such as dizziness, nausea and conscious disturbance but also could not effectively prevent allergic reactions caused by oxaliplatin. The findings provide information for clinical treatments that giving antihistamine drugs after allergic reactions occur due to oxaliplatin instead of giving it in advance for prevention not only reduces the complexity of the clinical implementation and adverse reactions caused by antihistamine drugs but also helps increase cost-effectiveness in all the aspects of medical treatment. Clinically, patient instructions about patient’s awareness of allergic reactions and self-care abilities, besides the often seen gastrointestinal side effects and neuropathy, should be enhanced, especially for the patients who have had allergic symptoms due to oxaliplatin and to more than 70% of whom it happens again after oxaliplatin re-challenge. Other preventive methods such as extending the time of oxaliplatin infusions or decreasing oxaliplatin dosage to reduce allergic reactions need more researches to verify their effectiveness.
8
Kiszkiel-Taudul, Ilona. "Ekstrakcyjne metody wydzielania wybranych leków przeciwhistaminowych i ich analiza w próbkach środowiskowych." Phd thesis, 2016. http://hdl.handle.net/11320/4826.
Повний текст джерелаАнотація:
Obecność związków biologicznie czynnych w środowisku może szkodliwie wpływać na zdrowie ludzi i ekosystemy wodne. Istotne jest zatem opracowanie procedur ekstrakcji zapewniających czułe i selektywne oznaczenie analitów. W badaniach opracowano, nieopisane dotąd w literaturze, metody wydzielania cymetydyny, nizatydyny, ranitydyny oraz famotydyny z próbek wodnych, które należą do grupy leków przeciwhistaminowych. Do wydzielania i rozdzielania ich mieszanin wykorzystano technikę ekstrakcji do fazy stałej (SPE), ekstrakcji micelarnej (ME) oraz ekstrakcji cieczowej wspomaganej ultradźwiękami (UAE). Ekstrakty analizowano za pomocą metod spektrofotometrycznych i chromatograficznych z różnymi rodzajami detekcji. W badaniach wykorzystano ekstrakcję za pomocą cieczy jonowych oraz zastosowano techniki zminiaturyzowane: mikroekstrakcję dyspersyjną (DLLME), mikroekstrakcję poprzez emulgację wspomaganą ultradźwiękami (USAEME) oraz mikroekstrakcję do pojedynczej kropli rozpuszczalnika (SDME). Takie rozwiązanie umożliwiło wzbogacanie analitów oraz obniżenie wartości granic ich wykrywalności. W badaniach opracowano także procedurę jednoczesnej ekstrakcji SPE omawianych związków i ich rozdzielenia za pomocą metody LC-MS/MS. Po wyznaczeniu parametrów analitycznych, opracowane procedury zastosowano do oznaczenia analitów w próbkach wód naturalnych i preparatach farmaceutycznych.The presence of biologically active compounds in the environment harmfully influences for human health and aquatic organisms. Therefore, the elaborating of the extraction procedures to assure detection of pharmaceuticals with high sensitivity and selectivity is significant. The new extraction methods for isolation of antihistaminic drugs (cimetidine, nizatidine, ranitidine and famotidine) from water samples were elaborated. The used procedures were not yet applied for separation of these compounds. The extraction and separation process of analytes was performed with using solid phase extraction (SPE), micellar extraction (ME) and ultrasound assisted extraction (UAE). The extracts were analyzed by using the spectrophotometric and chromatographic methods with different kind of detection. Miniaturized techniques: dispersive liquid-liquid microextraction (DLLME), ultrasound assisted emulsification microextraction (USAEME), single drop microextraction (SDME) and ionic liquids as extractants were used for isolation of the analytes. Developed methods allow for their preconcentration and decreasing of limit of detection. The SPE procedure for simultaneous isolation of compounds connected with chromatographic separation by using LC-MS/MS method was also elaborated. Developed procedures were used for determination of analytes in natural water samples and pharmaceutical preparations.
Wydział Biologiczno-Chemiczny. Instytut Chemii.
9
Magalhães, Gilberto Teixeira. "Intoxicações agudas por medicamentos de uso comum em pediatria." Master's thesis, 2021. http://hdl.handle.net/10284/10867.
Повний текст джерелаАнотація:
As intoxicações por medicamentos, de forma intencional ou não intencional, são um fator de mortalidade e morbilidade entre as crianças, sendo necessário, muitas das vezes, a hospitalização.
A identificação do agente tóxico, através do conjunto de sinais e sintomas, bem como o historial de exposição, é fundamental para que seja iniciado o tratamento/descontaminação o mais rápido possível de modo a diminuir o tempo de internamento e complicações de saúde.
O tratamento da intoxicação é diferente mediante o composto em causa e passa pelo tratamento sintomático, medidas de descontaminação e aumento da eliminação do tóxico.
Esta dissertação tem como objetivo efetuar uma revisão narrativa dos fármacos, ou grupos farmacoterapêuticos mais relatados em casos de intoxicações na idade pediátrica, destacando-se, em cada caso, as novas abordagens terapêuticas, algumas das quais ainda se encontram em fase de desenvolvimento clínico.Drug poisoning, whether internationally or not internationally, is an important factor of mortality and morbidity among children, often requiring hospitalization. The identification of the toxic agent, through the set of signs and symptoms, as well as the exposure history, is essential to start the treatment/decontamination, as soon as possible, in order to reduce hospitalization time and health complications. The treatment of intoxication is different according the compound and involves symptomatic treatment, decontamination measures and increased elimination of the toxicant. This dissertation aims to carry out a narrative review of the drugs, or pharmacotherapeutic groups most reported poisoning cases in pediatric age, highlighting, in each case, the new therapeutic approaches, some of which still in the clinical phases.
Книги з теми "ANTIHISTAMINE DRUGS"
1
1952-, Schlegel Robert E., Nesthus Thomas E, United States. Office of Aviation Medicine., University of Oklahoma. Dept. of Psychology., University of Oklahoma. School of Industrial Engineering., and Civil Aeromedical Institute, eds. Effects of antihistamine, age, and gender on task performance. Washington, D.C: U.S. Dept. of Transportation, Federal Aviation Administration, Office of Aviation Medicine, 1999.
Знайти повний текст джерела
2
R, Simons F. E., ed. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker, 2002.
Знайти повний текст джерела
3
(Canada), Expert Advisory Committee on Nonprescription Cough and Cold Remedies. First report. Ottawa: National Health and Welfare Canada, 1988.
Знайти повний текст джерела
4
Zemskov, Vladimir, and Veronika Zemskova. Immunotropic effects of therapeutic factors. ru: INFRA-M Academic Publishing LLC., 2020. http://dx.doi.org/10.12737/1039485.
Повний текст джерелаАнотація:
Data on the immunotropic effects of traditional drugs - antibiotics, antihistamines, anti-inflammatory, and metabolic agents-are summarized. The profile properties of cytostatics, immune globulins, cytokines, vaccines, interferons and their ability to develop General organizational effects are analyzed. Data on the types, blocks, principles of immunotherapy administration, and ways to prevent complications are highlighted.
For students and teachers, as well as employees of medical universities.
5
Niels, Mygind, and Naclerio Robert M. 1950-, eds. Rhinoconjunctivitis: New perspectives in topical treatment. Toronto: Hogrefe & Huber, 1989.
Знайти повний текст джерела
6
Divya, Vohora, ed. The third histamine receptor: Selective ligands as potential therapeutic agents in CNS disorders. Boca Raton: CRC Press, 2009.
Знайти повний текст джерела
7
R, Simons F. E., ed. Histamine and H1-receptor antagonists in allergic disease. New York: M. Dekker, 1996.
Знайти повний текст джерела
8
Baxter, Robert Ivan. Voltammetric studies of some important antihistamine drugs. 1985.
Знайти повний текст джерела
9
Simons, F. Estelle R. Histamine and H1-Antihistamines in Allergic Disease, Second Edition, (Clinical Allergy and Immunology). 2nd ed. Informa Healthcare, 2002.
Знайти повний текст джерела
10
The U.S. market for over-the-counter cough, cold, allergy and sinus products. New York, N.Y: Kalorama Information, 2005.
Знайти повний текст джерелаЧастини книг з теми "ANTIHISTAMINE DRUGS"
1
Källén, Bengt. "Maternal Use of Antihistamine Drugs for Allergy and Infant Congenital Malformations." In Maternal Drug Use and Infant Congenital Malformations, 383–88. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17898-7_34.
Повний текст джерела
2
Little, “Bert” Bertis Britt. "Antihistamines, Decongestants, and Expectorants during Pregnancy." In Drugs and Pregnancy, 231–40. 2nd ed. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9780429160929-11.
Повний текст джерела
3
De Vos, C., and J. P. Rihoux. "H1-Antihistamines." In New Drugs for Asthma, Allergy and COPD, 128–32. Basel: KARGER, 2001. http://dx.doi.org/10.1159/000062147.
Повний текст джерела
4
Saxena, Anil K., and Mridula Saxena. "Developments in antihistamines (H1)." In Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques, 35–125. Basel: Birkhäuser Basel, 1992. http://dx.doi.org/10.1007/978-3-0348-7144-0_3.
Повний текст джерела
5
Soldatos, C. R., and D. G. Dikeos. "Neuroleptics, Antihistamines and Antiparkinsonian Drugs: Effects on Sleep." In Handbook of Experimental Pharmacology, 443–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-57836-6_16.
Повний текст джерела
6
Fukui, Hiroyuki, Hiroyuki Mizuguchi, Hisao Nemoto, Yoshiaki Kitamura, Yoshiki Kashiwada, and Noriaki Takeda. "Histamine H1 Receptor Gene Expression and Drug Action of Antihistamines." In Handbook of Experimental Pharmacology, 161–69. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/164_2016_14.
Повний текст джерела
7
Crowe, Andrew. "Case Studies of Non-CNS Drugs to Minimize Brain Penetration-Nonsedative Antihistamines." In Blood-Brain Barrier in Drug Discovery, 463–81. Hoboken, NJ: John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118788523.ch21.
Повний текст джерела
8
Virginia Soldovieri, Maria, and Maurizio Taglialatela. "Cellular Mechanisms, Molecular Targets, and Structure-Function Relationships in Drug-Induced Arrhythmias: Antihistamines, Psychoactive Drugs, and Antimicrobial Agents." In Cardiotoxicity of Non-Cardiovascular Drugs, 47–96. Chichester, UK: John Wiley & Sons, Ltd, 2010. http://dx.doi.org/10.1002/9780470660379.ch3.
Повний текст джерела
9
Fukui, Hiroyuki, Hiroyuki Mizuguchi, Yoshiaki Kitamura, and Noriaki Takeda. "Clinical Significance of Histamine H1 Receptor Gene Expression and Drug Action of Antihistamines." In Histamine Receptors, 157–72. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40308-3_6.
Повний текст джерела
10
Vardanyan, Ruben, and Victor Hruby. "Antihistamine Drugs." In Synthesis of Best-Seller Drugs, 247–63. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-411492-0.00016-x.
Повний текст джерелаЗвіти організацій з теми "ANTIHISTAMINE DRUGS"
1
Schiflett, Samuel G. Antihistamine Drugs and Performance on C3 Tasks. Fort Belvoir, VA: Defense Technical Information Center, February 1992. http://dx.doi.org/10.21236/ada250762.
Повний текст джерела